Managing pediatric isolated growth hormone deficiency requires sustained treatment adherence over several years. Traditionally, daily recombinant human growth hormone therapy represents the standard clinical approach. However, daily injections often create significant emotional and physical burdens for pediatric patients and families. Non-adherence consequently hampers therapeutic outcomes, blunting final adult height. Fortunately, the development of once-weekly somatrogon provides a promising alternative to improve treatment compliance. Recent observational evidence evaluates how children switching to once-weekly somatrogon perform in real-world clinical environments over extended follow-up intervals.

Evaluating Once-Weekly Somatrogon in Real-World Cohorts

Clinical trials consistently confirm the non-inferiority of long-acting growth hormone formulations under controlled protocols. Nevertheless, real-world studies provide crucial insights into treatment performance within routine clinical practice. A notable retrospective investigation evaluated seventy-three children with isolated growth hormone deficiency who converted from daily injections to weekly therapy. The study cohort comprised fifty-two boys and twenty-one girls, presenting with a mean age of 12.56 years at transition. All seventy-three patients completed six months of structured follow-up, while fifty-eight and twenty-seven patients completed twelve and eighteen months, respectively. Researchers monitored height standard deviation scores alongside annualized height velocity metrics to evaluate longitudinal auxological trajectories. Furthermore, investigators tracked anthropometric parameters to determine whether therapeutic benefits persisted after leaving daily schedules. The results confirmed that patients maintained favorable linear growth without unexpected treatment interruptions. Therefore, this real-world evidence confirms that switching to weekly therapy preserves growth progression in routine outpatient care. Consequently, clinicians can adopt weekly regimens with high confidence.

Auxological Outcomes and Height Velocity Maintenance

Sustaining linear growth velocity remains the paramount therapeutic target in managing pediatric growth hormone deficiency. Throughout the eighteen-month observational period, height standard deviation scores increased progressively among treated children. Similarly, annualized height velocity standard deviation scores remained consistently positive across all evaluated follow-up checkpoints. This sustained velocity demonstrates that weekly therapy maintains catch-up growth momentum after discontinuing daily somatropin. Because previous daily therapy had already accelerated early linear growth, preserving positive velocity marks significant therapeutic success. Daily injection regimens frequently trigger treatment fatigue in peripubertal children. As a result, patients often miss doses, which gradually slows skeletal progression. Transitioning to weekly injections effectively overcomes injection resistance while sustaining continuous physiological growth stimulation. In addition, real-world height velocity improvements match those documented in pivotal randomized clinical trials. Endocrinologists can therefore reassure parents that reducing injection burden does not compromise overall stature development. Overall, the treatment switch preserves essential auxological gains across prolonged treatment durations.

Biochemical Surveillance and Serum IGF-1 Trajectories

Biochemical surveillance plays a critical role during pediatric growth hormone therapy to ensure therapeutic efficacy and safety. Specifically, circulating insulin-like growth factor-1 standard deviation score reflects physiological growth hormone receptor activation in target tissues. In the analyzed cohort, serum growth factor standard deviation scores demonstrated an early increase at six months post-switch. Subsequently, however, these biochemical values declined toward baseline ranges by twelve and eighteen months of follow-up. Pediatric endocrinologists must recognize this characteristic temporal pattern when assessing outpatient laboratory panels. The pharmacokinetic differences between daily injections and weekly sustained-release formulations explain these initial biochemical fluctuations. Therefore, clinicians should avoid premature dose reductions when encountering modest early increases without adverse clinical signs. Moreover, clinical teams should standardize blood sampling schedules relative to weekly injection days to maintain monitoring consistency. Accurate tracking ensures that patients avoid supra-physiological hormone exposure while sustaining therapeutic efficacy. Thus, structured biochemical surveillance remains a cornerstone of individualized patient management.

Body Mass Index Evolution and Metabolic Considerations

Growth hormone exerts potent metabolic effects, stimulating protein synthesis, promoting lipolysis, and altering body composition. Accordingly, investigators examined body mass index standard deviation scores and weight trajectories throughout the transition period. During the first twelve months post-transition, patients exhibited a significant rise in body mass index standard deviation score. However, this metric stabilized completely by eighteen months of continued therapy. This biphasic pattern reflects normal physiological redistributions of lean muscle tissue, extracellular water volume, and adipose tissue during puberty. Because growth hormone therapy modulates somatic growth and lean mass, early weight gain does not automatically signify excess adiposity. Clinicians should nevertheless counsel families regarding healthy nutritional habits and routine physical activity to prevent unwanted fat accumulation. Furthermore, clinicians should evaluate fasting glucose, lipid parameters, and glycated hemoglobin during routine checkups. Consequently, thorough metabolic monitoring distinguishes physiological tissue expansion from pathological weight gain, ensuring holistic pediatric care.

Clinical Application and Guidance for Indian Practitioners

In India, managing pediatric growth hormone deficiency requires addressing substantial socioeconomic, cultural, and logistical hurdles. Daily injections often impose immense psychological stress on young children and create substantial administrative burdens for working parents. Consequently, non-compliance frequently arises, undermining long-term height velocity and therapeutic investment. Transitioning stable patients to once-weekly somatrogon reduces injection frequency from 365 injections to just 52 annually. This dramatic reduction significantly enhances patient convenience, quality of life, and treatment adherence across diverse demographics. Nevertheless, Indian clinicians must ensure proper caregiver training regarding cold-chain refrigeration, pen-device administration, and dose verification. Furthermore, treating teams should conduct periodic auxological assessments every three to six months to verify adequate catch-up growth. Providers should also monitor serum insulin-like growth factor-1 concentrations systematically to safeguard against improper dosing. Although product availability and treatment expenditure remain important practical considerations in private practice, weekly options modernize pediatric endocrine care. Ultimately, proactive physician guidance ensures optimal growth outcomes while substantially minimizing pediatric injection anxiety.

How does switching to once-weekly somatrogon affect linear growth in pediatric GHD?

Switching from daily growth hormone to once-weekly somatrogon effectively maintains positive height velocity and improves height standard deviation scores over extended follow-up. Real-world studies confirm that children transitioning to weekly therapy experience linear growth preservation comparable to daily somatropin regimens. Furthermore, reducing injection frequency significantly enhances therapeutic compliance, preventing height deceleration caused by missed daily doses. Consequently, pediatric patients can achieve their targeted adult height potential without compromising linear growth trajectory.

Why do serum IGF-1 levels fluctuate following transition to weekly therapy?

Serum insulin-like growth factor-1 standard deviation scores typically exhibit an early increase during the first six months after transition before stabilizing or declining. This transient rise reflects altered pharmacokinetics and hepatic exposure associated with long-acting molecules compared to daily formulations. Therefore, pediatric endocrinologists should interpret early growth factor elevations prudently and standardize blood draw timing relative to the weekly injection. Routine surveillance prevents unnecessary dose reductions while ensuring ongoing safety and physiological hormone exposure.

How should clinicians manage body mass index changes during weekly treatment?

Children undergoing transition to weekly somatrogon may experience a transient rise in body mass index standard deviation score during the first year, which typically plateaus by eighteen months. This temporary change often stems from pubertal growth spurts, shifting muscle-to-fat distribution, and fluid redistributions induced by growth hormone. Consequently, physicians should monitor anthropometric and metabolic parameters continuously. Combining routine clinical tracking with lifestyle and nutritional counseling helps ensure healthy body composition without requiring treatment discontinuation.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Healthcare professionals should exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Sotiriou G et al. Transition to once-weekly growth hormone in paediatric isolated growth hormone deficiency: A real-world experience. Eur J Endocrinol. 2026 Sep 24. doi: undefined. PMID: 42779506.
2. Deal CL, Steelman J, Gardner M, et al. Once-weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717-e2728.
3. Miller BS, Velazquez E, Yuen KCJ, et al. Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement. J Clin Endocrinol Metab. 2025;110(5):1120-1135.